Eli Lilly and Co. received approval from the FDA for a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Taltz is the first and only treatment approved by the FDA for moderate-to-severe plaque psoriasis that includes such data in its label. Taltz was first approved by the FDA in March 2016 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In December 2...